DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Announcement
December 14, 2023

MQA Online Services will be unavailable from Friday, December 15, at 6:00 PM to December 17, at 12:00 PM EST. Continue reading


Announcing the FY 2022-23 Annual Report and Long-Range Plan
November 1, 2023

An annual publication showcasing trends and information about Florida’s health care regulatory landscape. Continue reading